Linked Life Data

21506152

Source:http://linkedlifedata.com/resource/pubmed/id/21506152

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:21506152rdf:typepubmed:Citationlld:pubmed
pubmed-article:21506152lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:21506152lifeskim:mentionsumls-concept:C0229671lld:lifeskim
pubmed-article:21506152lifeskim:mentionsumls-concept:C0024408lld:lifeskim
pubmed-article:21506152lifeskim:mentionsumls-concept:C1515926lld:lifeskim
pubmed-article:21506152pubmed:issue4lld:pubmed
pubmed-article:21506152pubmed:dateCreated2011-4-20lld:pubmed
pubmed-article:21506152pubmed:abstractTextSpinocerebellar ataxias (SCAs) constitute a group of autosomal dominant neurodegenerative disorders with no current treatment. The insulin/insulin-like growth factor 1 (IGF-1) system (IIS) has been shown to play a role in the neurological dysfunction of SCAs and other polyglutamine disorders. We aimed to study the biomarker profile of serum IIS components in SCA3. We performed a case-control study with 46 SCA3 patients and 42 healthy individuals evaluating the peripheral IIS profile (insulin, IGF-1, IGFBP1 and 3) and the correlation with clinical, molecular, and neuroimaging findings. SCA3 patients presented lower insulin and IGFBP3 levels and higher insulin sensitivity (HOMA2), free IGF-I, and IGFBP1 levels when compared with controls. IGFBP-1 levels were directly associated with CAG expanded repeat length; IGF-1 was associated with the volumetries of specific brainstem regions on magnetic resonance imaging (MRI). Insulin levels and sensitivity were related to age at onset of symptoms. Our findings indicate an involvement of IIS components in SCA3 neurobiology and IGFBP-1 as a potential biomarker of the disease.lld:pubmed
pubmed-article:21506152pubmed:languageenglld:pubmed
pubmed-article:21506152pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21506152pubmed:citationSubsetIMlld:pubmed
pubmed-article:21506152pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21506152pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21506152pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21506152pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21506152pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21506152pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21506152pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21506152pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21506152pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21506152pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21506152pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21506152pubmed:statusMEDLINElld:pubmed
pubmed-article:21506152pubmed:monthMarlld:pubmed
pubmed-article:21506152pubmed:issn1531-8257lld:pubmed
pubmed-article:21506152pubmed:authorpubmed-author:SouzaDiogo...lld:pubmed
pubmed-article:21506152pubmed:authorpubmed-author:Torres-Aleman...lld:pubmed
pubmed-article:21506152pubmed:authorpubmed-author:ArpaJavierJlld:pubmed
pubmed-article:21506152pubmed:authorpubmed-author:PortelaLuis...lld:pubmed
pubmed-article:21506152pubmed:authorpubmed-author:SauteJonas...lld:pubmed
pubmed-article:21506152pubmed:authorpubmed-author:VedolinLeonar...lld:pubmed
pubmed-article:21506152pubmed:authorpubmed-author:JardimLaura...lld:pubmed
pubmed-article:21506152pubmed:authorpubmed-author:HanselGiseleGlld:pubmed
pubmed-article:21506152pubmed:authorpubmed-author:MullerAlexand...lld:pubmed
pubmed-article:21506152pubmed:authorpubmed-author:Saraiva-Perei...lld:pubmed
pubmed-article:21506152pubmed:authorpubmed-author:da...lld:pubmed
pubmed-article:21506152pubmed:authorpubmed-author:de...lld:pubmed
pubmed-article:21506152pubmed:authorpubmed-author:MaedaFábioFlld:pubmed
pubmed-article:21506152pubmed:copyrightInfoCopyright © 2010 Movement Disorder Society.lld:pubmed
pubmed-article:21506152pubmed:issnTypeElectroniclld:pubmed
pubmed-article:21506152pubmed:volume26lld:pubmed
pubmed-article:21506152pubmed:ownerNLMlld:pubmed
pubmed-article:21506152pubmed:authorsCompleteYlld:pubmed
pubmed-article:21506152pubmed:pagination731-5lld:pubmed
pubmed-article:21506152pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:21506152pubmed:meshHeadingpubmed-meshheading:21506152...lld:pubmed
pubmed-article:21506152pubmed:meshHeadingpubmed-meshheading:21506152...lld:pubmed
pubmed-article:21506152pubmed:meshHeadingpubmed-meshheading:21506152...lld:pubmed
pubmed-article:21506152pubmed:meshHeadingpubmed-meshheading:21506152...lld:pubmed
pubmed-article:21506152pubmed:meshHeadingpubmed-meshheading:21506152...lld:pubmed
pubmed-article:21506152pubmed:meshHeadingpubmed-meshheading:21506152...lld:pubmed
pubmed-article:21506152pubmed:meshHeadingpubmed-meshheading:21506152...lld:pubmed
pubmed-article:21506152pubmed:meshHeadingpubmed-meshheading:21506152...lld:pubmed
pubmed-article:21506152pubmed:meshHeadingpubmed-meshheading:21506152...lld:pubmed
pubmed-article:21506152pubmed:meshHeadingpubmed-meshheading:21506152...lld:pubmed
pubmed-article:21506152pubmed:meshHeadingpubmed-meshheading:21506152...lld:pubmed
pubmed-article:21506152pubmed:meshHeadingpubmed-meshheading:21506152...lld:pubmed
pubmed-article:21506152pubmed:meshHeadingpubmed-meshheading:21506152...lld:pubmed
pubmed-article:21506152pubmed:meshHeadingpubmed-meshheading:21506152...lld:pubmed
pubmed-article:21506152pubmed:meshHeadingpubmed-meshheading:21506152...lld:pubmed
pubmed-article:21506152pubmed:year2011lld:pubmed
pubmed-article:21506152pubmed:articleTitleSerum insulin-like system alterations in patients with spinocerebellar ataxia type 3.lld:pubmed
pubmed-article:21506152pubmed:affiliationDepartment of Biochemistry, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.lld:pubmed
pubmed-article:21506152pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:21506152pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed